{"name":"IRCCS Eugenio Medea","slug":"irccs-eugenio-medea","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Etravirine Tablets","genericName":"Etravirine Tablets","slug":"etravirine-tablets","indication":"HIV-1 infection","status":"phase_2"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"methyphenidate","genericName":"methyphenidate","slug":"methyphenidate","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"Etravirine Tablets","genericName":"Etravirine Tablets","slug":"etravirine-tablets","phase":"phase_2","mechanism":"Non-nucleoside reverse transcriptase inhibitor","indications":["HIV-1 infection"],"catalyst":""},{"name":"methyphenidate","genericName":"methyphenidate","slug":"methyphenidate","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi-AFBVV95cUxOT3NQdEd6bTJONzZNanVoV0xXcmZzOWdnUHZIRGVPOUs4RkpUb1ZyekdFdHJwY0FLREd1a3dueUFEWkN3cFdxVHE1TTk2cExEdXRnNExXTV9PdGJjRTg3NEExWmdpbnFLcXpoQV9MMHg1YUQ0UWFWRkYwbVZOaDVrLXRkaXAtV19DbThoQ3FoWEczTE9WMzBEck9EU25jNWt5WlhlSjBxRHpVNF9odjRlUDB1Q1pnYm0xNTVuVTI4N0xWd0lhQWFSV1hTaWpzSlh1RFhVNkVfRGRFM1EwUm0zcFlXNjVNWFQxQXpwSkFLbXJicnktd2RlcQ?oc=5","date":"2025-03-03","type":"pipeline","source":"Ricerca Malattie Genetiche Rare","summary":"A platform dedicated to Duchenne Muscular Dystrophy - Ricerca Malattie Genetiche Rare","headline":"A platform dedicated to Duchenne Muscular Dystrophy","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_2":2},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}